One of the benefits of surgical robotics is the potential to bring standardized precision to procedures performed almost anywhere and by almost anyone. However, most systems have focused on everything below the neck.
ForSight Robotics aims to bring the same advantages to eye surgery and has raised $10 million to embark on building a miniaturized system with the goal of bringing vision-correcting procedures to a wider population.
The seed round, backed by Eclipse Ventures and Mithril Capital, will support ForSight’s plans to integrate microsurgical robotics with computer vision and machine learning algorithms, which will study past eye procedures to help replicate the expertise held by ophthalmic surgeons facing high demand—with many countries only having a few to several dozen trained professionals per million people.
“Our goal is to democratize this highly sophisticated procedure, enabling patients around the world to easily access the treatment that can restore their vision,” said ForSight’s co-founder and CEO, Daniel Glozman, who previously held roles at Medtronic Ventor Technologies, Magenta Medical, Diagnostic Robotics and Guide-X.
The company was also co-founded by Moshe Shoham, who previously established Mazor Robotics before its acquisition by Medtronic, and Joseph Nathan, who helped lead healthcare commercialization at the Technion Israel Institute of Technology and directed new venture work at the center’s Alfred Mann Institute.
Meanwhile, the Israel-based company’s strategic advisory board includes robotics pioneer Fred Moll, M.D., co-founder of Intuitive Surgical and Auris Health, plus Mako Surgical and Magic Leap co-founder Rony Abovitz and Mithril co-founder Ajay Royan.
“As populations grow and age, robotically assisted surgery is an essential tool to simultaneously advance technique and broaden access to top-tier medical expertise,” Royan said. “ForSight’s mission will benefit hundreds of millions around the world.”
The company’s platform aims to provide surgeons with full freedom of movement while manipulating tools with precise movements amounting to a few microns combined with 3D imaging and real-time guidance.
by Conor Hale
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.